These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 33917020)

  • 21. Association of thrombopoietin-related drugs with thromboembolic events: Mendelian randomization and a real-world study.
    Liang C; Chen Q; Zhang Y
    Ther Adv Drug Saf; 2024; 15():20420986231224236. PubMed ID: 38293563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
    Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
    Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hematological toxicity of cyclin-dependent kinase 4/6 inhibitors in patients with breast cancer: a network meta-analysis and pharmacovigilance study.
    Ding H; Xu W; Dai M; Li S; Xin W; Tong Y; He C; Mi X; Zhan Z; Fang L
    Expert Opin Drug Saf; 2024 May; ():1-9. PubMed ID: 38753541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
    Raschi E; Poluzzi E; Koci A; Antonazzo IC; Marchesini G; De Ponti F
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):380-6. PubMed ID: 27067162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
    Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
    Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Fusaroli M; Giunchi V; Repaci A; Pelusi C; Mollica V; Massari F; Ardizzoni A; Poluzzi E; Pagotto U; Di Dalmazi G
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230533
    [No Abstract]   [Full Text] [Related]  

  • 30. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
    Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
    Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal.
    Raschi E; Fusaroli M; Gatti M; Caraceni P; Poluzzi E; De Ponti F
    Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Vestergaard Kvist A; Faruque J; Vallejo-Yagüe E; Weiler S; Winter EM; Burden AM
    J Clin Med; 2021 Apr; 10(8):. PubMed ID: 33924496
    [No Abstract]   [Full Text] [Related]  

  • 35. Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems.
    Raschi E; Girardi A; Poluzzi E; Forcesi E; Menniti-Ippolito F; Mazzanti G; De Ponti F
    Drug Saf; 2018 Aug; 41(8):745-752. PubMed ID: 29582393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.
    Sato K; Mano T; Iwata A; Toda T
    Biosci Trends; 2020 May; 14(2):139-143. PubMed ID: 32321905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019.
    Ye X; Hu F; Zhai Y; Qin Y; Xu J; Guo X; Zhuang Y; He J
    Hematol Oncol; 2020 Oct; 38(4):565-575. PubMed ID: 32383782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Fibrates and risk of venous thromboembolism: Case/no-case study in French pharmacovigilance database].
    Humbert X; Dolladille C; Sassier M; Valnet-Rabier MB; Vial T; Guitton E; Page A; Sole E; Auriche P; Coquerel A; Alexandre J; Fedrizzi S
    Therapie; 2017 Dec; 72(6):677-682. PubMed ID: 28941579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA adverse event reporting system database.
    Gandhi PK; Gentry WM; Bottorff MB
    Semin Arthritis Rheum; 2013 Jun; 42(6):562-6. PubMed ID: 23352248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Laderian B; Fojo T
    Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.